ArticleRevista da Associacao Medica Brasileira (1992)2025
Investigation of the relationship between venous thromboembolism and thrombophilic variants.
Article in Revista da Associacao Medica Brasileira (1992), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveVenous thromboembolism could be manifested as deep venous thrombosis or pulmonary embolism. The aim of this study was to assess the impact of genetic risk factors including prothrombin 20210, Factor V Leiden, plasminogen activator inhibitor 4G/5G, and Factor XIII V34L on the occurrence of venous thromboembolism in patients.
methodsThis study was conducted on 128 patients with deep venous thrombosis and 84 patients with pulmonary embolism. The diagnosis of venous thromboembolism was based on the patient's history, clinical findings, and D-dimer and confirmed by Doppler ultrasonography or computed tomography angiography. After confirmation of venous thromboembolism diagnosis, both groups were assessed for the four abovementioned mutations.
resultsThe majority of deep venous thrombosis patients were much younger than pulmonary embolism patients, with a median age of 51.7 years. It was observed that plasminogen activator inhibitor 4G/5G was most commonly represented in the deep venous thrombosis (44.5%) group, followed by the pulmonary embolism (44.0%) group. The second-highest frequency of Factor XIII V34L was observed in the deep venous thrombosis (28.1%) and pulmonary embolism (32.1%) groups. Factor V Leiden heterozygosity was also common in the deep venous thrombosis (18.0%) and pulmonary embolism (27.4%) groups. We found that coagulation factor II (FII) G20210A heterozygosity was the least in the deep venous thrombosis (10.9%) and pulmonary embolism (9.5%) groups.
conclusionTo date, only a few studies have been thrombophilia parameters associated with venous thromboembolism, particularly Factor XIII V34L, in Turkish population with venous thromboembolism patients. Our findings suggest that genetic risk factors play a role in the formation of venous thromboembolism.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.